Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer
- 1 May 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (5), 1425
- https://doi.org/10.1200/jco.1999.17.5.1425
Abstract
PURPOSE: To determine the efficacy and safety profile, including the risk for cardiac toxicity, of liposome-encapsulated doxorubicin (TLC D-99), fluorouracil (5-FU), and cyclophosphamide as first-l...Keywords
This publication has 16 references indexed in Scilit:
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.Journal of Clinical Oncology, 1997
- Anthracycline-Induced CardiotoxicityAnnals of Internal Medicine, 1996
- Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.Journal of Clinical Oncology, 1994
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensBritish Journal of Cancer, 1993
- Strategies for prevention of anthracycline cardiotoxicityCancer Treatment Reviews, 1993
- Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinomaCancer, 1989
- Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly ScheduleAnnals of Internal Medicine, 1983
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979